Improving theranostics in pancreatic cancer.


BACKGROUND Pancreatic cancer is the fourth most deadly cancer in the United States, and is expected to be the second most deadly by 2030. The major difficulty in treating pancreatic cancer is the late onset of symptoms. Generally, patients show metastatic disease by the time of diagnosis, with a survival rate of 5% beyond 5 years. In patients without… (More)
DOI: 10.1002/jso.24625


Cite this paper

@article{King2017ImprovingTI, title={Improving theranostics in pancreatic cancer.}, author={Jeremy A King and Michael Bouvet and Gagandeep Singh and John Williams}, journal={Journal of surgical oncology}, year={2017}, volume={116 1}, pages={104-113} }